BGC Partners Inc.

10/19/2021 | Press release | Distributed by Public on 10/19/2021 05:55

Material Event - Form 8-K


Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 18, 2021
BGC Partners, Inc.
(Exact name of Registrant as specified in its charter)
Delaware 0-28191 13-4063515
(State or other jurisdiction
of incorporation)
File Number)
(I.R.S. Employer
Identification No.)
499 Park Avenue, New York, NY10022
(Address of principal executive offices)
Registrant's telephone number, including area code: (212) 610-2200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Class A Common Stock, $0.01 par value BGCP The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events.

On October 18, 2021, Howard W. Lutnick, Chairman of the Board and Chief Executive Officer of BGC Partners, Inc. (the "Company"), informed the employees of the Company via video that he was recently diagnosed with Non-Hodgkin's Lymphoma. Mr. Lutnick's form of cancer is highly treatable and he and his physicians expect that he will be cancer-free in four months. Mr. Lutnick's treatment plan includes six chemotherapy treatments beginning on October 18, 2021 and running through the end of January 2022. Mr. Lutnick expects to continue to serve the Company during this time. The video is available on the Company's website at The video is also available at and

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
BGC Partners, Inc.
Date: October 19, 2021 By: /s/ Howard W. Lutnick
Name: Howard W. Lutnick
Title: Chairman of the Board and Chief Executive Officer
[Signature Page to Form 8-K, dated October 19, 2021]